2,555
+1.59%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About iNtRON Biotechnology
Its shares trade on KOSDAQ under the ticker 048530.KQ. It has been listed since 26 January 2011. In the fiscal year to 31 December 2025, it reported revenue of ₩5.74bn and a net loss of ₩8.96bn. At that date it held total assets of ₩74.32bn and shareholders' equity of ₩69.87bn.
iNtRON Biotechnology, Inc. engages in the development of super-bacteria treatment, antibiotics alternatives, bio new drug, molecular diagnostics and artificial blood. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2011-01-26. The firm operates its business through two main divisions: genetic reagent division and molecular diagnostics division. Its genetic reagent division is involved in the research and development of reagents, which are under the brand names of Maxime and pLUG for life science research. Its molecular diagnostics division is engaged in the development and production of nucleic acid tester for infectious diseases. The company also engages in the operation of veterinary antibiotic alternative business and new biopharmaceuticals development business. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Jan 2011
- Website
- intron.co.kr ↗
Leadership
Pay as last reported
- Mr. Seong Jun YoonPresident, Co-Chief Executive Officer, Director
- Mr. Gyeong Won YoonCo-Chief Executive Officer, Vice President, Director, since 2021
- Mr. Sang Hyeon KangVice President, Director, since 2022
- Mr. Jae Gu SulManaging Director, since 2013
- Ms. Su Yeon JeonAssistant Managing Director
- Ms. Ji Seong ParkAssistant Managing Director
- Ms. Man Sun ParkAssistant Managing Director
- Mr. Jong Seong YoonInternal Auditor
- Mr. Myeong Hun SungNon-Executive Independent Director
- Ms. Yun Seon YangNon-Executive Independent Director
- Seong Wu KimIR Contact Officer, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- iNtRON Biotechnology's Maxime and pLUG reagents support life science research with strong market presence.
- The company's molecular diagnostics division develops nucleic acid testers for infectious diseases globally.
- iNtRON's veterinary antibiotic alternative business addresses growing demand for sustainable treatments.
Weaknesses
- The company's genetic reagent division relies on Maxime and pLUG brand names for research applications.
- Limited international market expansion beyond domestic and overseas distribution channels.
- Dependence on biopharmaceuticals development for new drug innovation within the Health Care sector.
Opportunities
- Growing demand for super-bacteria treatment solutions in the Health Care industry.
- Expansion of molecular diagnostics for infectious disease testing in global markets.
- Increasing focus on bio new drug development within the Biotechnology sector.
Threats
- Competition in the biopharmaceuticals market for new drug development.
- Regulatory challenges in the molecular diagnostics division for infectious disease testing.
- Market saturation in veterinary antibiotic alternatives within the Health Care sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.